Last reviewed · How we verify

NCT05561127: PATENT-B

Paclitaxel Coated Balloon for the Treatment of Chronic bEnigN sTricture- Bowel

Recruiting now Phase 3 Last updated 25 June 2025
What this trial tests

Phase 3 trial testing GIE Medical ProTractX3 TTS DCB in Bowel; Stricture in 171 participants. Currently enrolling.

Timeline
1 November 2023
Primary endpoint
1 December 2027
1 June 2032

Quick facts

Lead sponsorGIE Medical
PhasePhase 3
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment171
Start date1 November 2023
Primary completion1 December 2027
Estimated completion1 June 2032
Sites33 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

GIE Medical

Who can join

22 and older, any sex, with Bowel; Stricture. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To determine the safety and efficacy of GIE Medical's ProTractX3™ TTS DCB for the treatment of recurrent benign bowel strictures.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Initial safety and efficacy of a novel drug-coated balloon for treatment of benign intestinal strictures.
    Shen B, Adorno-Garayo CR. · · 2024 · cited 3× · PMID 41648897 · DOI 10.1016/j.igie.2023.12.002

Verify or expand the search:

Other GIE Medical trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05561127.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing